AA
OCUL icon

ALPS Advisors’s Ocular Therapeutix OCUL Stock Holding History

ALPS Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-28,587
Closed -$177K – 870
2017
Q3 		$177K Buy
28,587
+2,386
+9% +$15.4K ﹤0.01% 760
2017
Q2 		$243K Buy
26,201
+1,462
+6% +$14.2K ﹤0.01% 736
2017
Q1 		$230K Buy
24,739
+830
+3% +$6.91K ﹤0.01% 706
2016
Q4 		$200K Sell
23,909
-7,734
-24% -$60K ﹤0.01% 697
2016
Q3 		$217K Sell
31,643
-3,149
-9% -$19.2K ﹤0.01% 655
2016
Q2 		$172K Buy
34,792
+6,976
+25% +$69.1K ﹤0.01% 601
2016
Q1 		$269K Sell
27,816
-4,767
-15% -$36.1K ﹤0.01% 584
2015
Q4 		$305K Sell
32,583
-6,082
-16% -$65.7K ﹤0.01% 649
2015
Q3 		$5.44K Buy
38,665
+14,182
+58% +$285K 0.01% 271
2015
Q2 		$515K Buy
+24,483
New +$607K ﹤0.01% 472

Other funds holding OCUL

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ALPS Advisors's OCUL Position: Q4 2017 in Review

ALPS Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2017, closing a stake of 28,587 shares — an estimated $177K sold.

ALPS Advisors first reported a position in OCUL in Q2 2015 and held it in 10 quarters. The position peaked at $515K in Q2 2015. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2017.

  • ALPS Advisors reported no remaining Ocular Therapeutix position as of Q4 2017 after selling out during the quarter.
  • ALPS Advisors sold 28,587 Ocular Therapeutix shares in Q4 2017, an estimated $177K.
  • ALPS Advisors first reported a position in Ocular Therapeutix in Q2 2015 and held it in 10 quarters.
  • ALPS Advisors's Ocular Therapeutix position peaked at $515K in Q2 2015.
  • 69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2017.

Based on ALPS Advisors's 13F filing for Q4 2017, filed 5 Feb 2018.